U.S. markets close in 3 hours 20 minutes

Aravive, Inc. (ARAV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.8700-0.0700 (-1.42%)
As of 12:18PM EDT. Market open.

Aravive, Inc.

River Oaks Tower
Suite 1200 3730 Kirby Drive
Houston, TX 77098
United States
936 355 1910

Full Time Employees16

Key Executives

NameTitlePayExercisedYear Born
Dr. Gail F. McIntyreCEO & Director453.34kN/A1963
Mr. Vinay ShahChief Financial Officer463.51kN/A1962
Dr. Jeffrey L. ClelandCo-FounderN/AN/A1965
Dr. Joshua Silverman Ph.D.Co-FounderN/AN/AN/A
Dr. Randy L. AndersonSr. VP of Data SciencesN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, triple negative breast cancer, acute myeloid leukemia, and pancreatic cancer. The company has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.

Corporate Governance

Aravive, Inc.’s ISS Governance QualityScore as of December 9, 2019 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.